Hims & Hers Health (NYSE:HIMS) Lowered to “Hold” Rating by Leerink Partners

Leerink Partners cut shares of Hims & Hers Health (NYSE:HIMS) from a strong-buy rating to a hold rating in a research report sent to investors on Tuesday,Zacks.com reports.

A number of other analysts also recently commented on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday, December 29th. BTIG Research downgraded Hims & Hers Health from a “buy” rating to a “neutral” rating in a research note on Tuesday. Truist Financial reiterated a “hold” rating and set a $18.00 target price (down from $37.00) on shares of Hims & Hers Health in a research note on Tuesday. Citigroup reduced their price target on shares of Hims & Hers Health from $16.50 to $13.25 and set a “sell” rating for the company in a research report on Tuesday. Finally, TD Cowen decreased their price objective on shares of Hims & Hers Health from $20.00 to $17.00 and set a “hold” rating for the company in a report on Tuesday. Two research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus target price of $32.27.

Hims & Hers Health Price Performance

HIMS opened at $15.43 on Tuesday. Hims & Hers Health has a 1 year low of $13.74 and a 1 year high of $70.43. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. The company has a market capitalization of $3.51 billion, a price-to-earnings ratio of 30.26, a P/E/G ratio of 2.90 and a beta of 2.43. The firm’s fifty day moving average price is $27.79 and its two-hundred day moving average price is $39.76.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.25%. The company had revenue of $617.82 million for the quarter, compared to analyst estimates of $619.48 million. During the same period last year, the firm earned $0.11 earnings per share. The firm’s revenue was up 28.4% on a year-over-year basis. As a group, analysts anticipate that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health declared that its board has authorized a stock repurchase program on Monday, November 17th that allows the company to repurchase $250.00 million in shares. This repurchase authorization allows the company to buy up to 3% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s leadership believes its shares are undervalued.

Insider Activity at Hims & Hers Health

In related news, insider Deborah M. Autor sold 7,054 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $258,952.34. Following the completion of the transaction, the insider directly owned 6,175 shares of the company’s stock, valued at approximately $226,684.25. This trade represents a 53.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Irene Becklund sold 8,411 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $308,767.81. Following the completion of the transaction, the insider owned 2,126 shares of the company’s stock, valued at $78,045.46. This represents a 79.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 82,963 shares of company stock worth $2,944,621 in the last ninety days. Insiders own 17.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds have recently made changes to their positions in the stock. MidFirst Bank bought a new stake in shares of Hims & Hers Health during the 4th quarter valued at $146,000. Pacer Advisors Inc. increased its position in shares of Hims & Hers Health by 83.6% during the fourth quarter. Pacer Advisors Inc. now owns 50,054 shares of the company’s stock valued at $1,625,000 after buying an additional 22,794 shares during the period. Virtu Financial LLC purchased a new stake in shares of Hims & Hers Health in the fourth quarter worth about $1,937,000. Axxcess Wealth Management LLC purchased a new stake in shares of Hims & Hers Health in the fourth quarter worth about $914,000. Finally, Creek Drive Management Group LLC bought a new position in shares of Hims & Hers Health in the fourth quarter valued at approximately $3,767,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Q4 beat on profitability and continued top-line growth — HIMS beat EPS expectations and reported ~28% revenue growth with subscribers topping 2.5 million, showing demand resilience in its core telehealth business. Business Wire: Q4 results
• Positive Sentiment: Longer-term revenue upside from international expansion — Management reiterated FY‑2026 revenue guidance above Street estimates and finalized the acquisition of Eucalyptus (up to ~$1.15B), which management says will accelerate international revenue and diversify growth beyond U.S. weight‑loss offerings. Reuters: 2026 revenue forecast
• Neutral Sentiment: Unusual options activity — Heavy call buying occurred ahead of/around the results (large uptick in call volume), which can amplify intraday moves but does not change the company’s fundamentals.
• Negative Sentiment: Regulatory and legal overhang — The SEC opened an investigation into HIMS’ disclosures on compounded GLP‑1s, and Novo Nordisk sued over alleged patent infringement tied to compounded semaglutide; HIMS has withdrawn its compounded product. These developments raise liability, compliance costs, and uncertainty for the core weight‑loss segment. Yahoo Finance: SEC probe & legal issues
• Negative Sentiment: Analyst downgrades and price-target cuts — Multiple firms downgraded HIMS (Leerink, BTIG) and Citigroup cut its target to $13.25 with a sell rating, contributing to downward pressure and a new 52‑week low on heightened bearish sentiment. Benzinga: analyst cuts AmericanBankingNews: 52-week low
• Negative Sentiment: Soft near-term guidance and margin pressure — Although FY revenue guidance was raised, Q1 revenue guidance came in below estimates and management signaled margin/headwind items (change in shipping cadence, marketing/advertising like the Super Bowl spot), prompting concern that near-term profitability could be pressured. Zacks: margins and guidance

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.